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Background: Infantile hemangiomas are benign vascular tumors primarily found on the skin in 10% of the
pediatric population. The etiology of this disease is largely unknown and while large scale genomic studies have
examined the transcriptomes of infantile hemangioma tumors as a whole, no study to date has compared the
global gene expression profiles of pure infantile hemangioma endothelial cells (HEMECs) to that of normal human
dermal microvascular endothelial cells (HDMVECs).
Methods: To shed light on the molecular differences between these normal and aberrant dermal endothelial cell
types, we performed whole genome microarray analysis on purified cultures of HEMECs and HDMVECs. We then
utilized qPCR and immunohistochemistry to confirm our microarray results.
Results: Our array analysis identified 125 genes whose expression was upregulated and 104 genes whose
expression was downregulated by greater than two fold in HEMECs compared to HDMVECs. Bioinformatics analysis
revealed three major classifications of gene functions that were altered in HEMECs including cell adhesion, cell
cycle, and arachidonic acid production. Several of these genes have been reported to be critical regulators and/or
mutated in cancer, vascular tumors, and vascular malformations. We confirmed the expression of a subset of these
differentially expressed genes (ANGPT2, ANTXR1, SMARCE1, RGS5, CTAG2, LTBP2, CLDN11, and KISS1) using qPCR
and utilized immunohistochemistry on a panel of paraffin embedded infantile hemangioma tumor tissues to
demonstrate that the cancer/testis antigen CTAG2 is highly abundant in vessel-dense proliferating infantile
hemangiomas and with significantly reduced levels during tumor involution as vascular density decreases.
Conclusion: Our data reveal that the transcriptome of HEMECs is reflective of a pro-proliferative cell type with
altered adhesive characteristics. Moveover, HEMECs show altered expression of many genes that are important in
the progression and prognosis of metastatic cancers.* Correspondence: brad.bryan@ttuhsc.edu
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Infantile hemangiomas are benign tumors of vascular
origin that affect approximately 10% of the pediatric
population. These tumors are characterized by a rapid
proliferation phase over the first 1–2 years of the child’s
life, followed by a slow and steady decline over the next
5–7 years leading to the complete involution of the
tumor mass. Approximately 90% of all infantile hemangi-
omas remain small and are best left alone to naturally
involute. However in about 10% of the cases the tumors
exhibit aggressive characteristics based on their size, loca-
tion, number, etc. and must be actively treated to avoid
patient disfigurement and/or mortality.
The etiology of infantile hemangiomas is largely un-
known, particularly with regard to the cellular origin of
the tumor. Circumstantial evidence suggests that these le-
sions are of aberrant placental origin as evidenced by
upregulated Glut1 expression [1], and some labs have ven-
tured to hypothesize that they may be formed from meta-
static invasion of placenta-derived chorangioma cells [2].
Indeed, transcriptional profiling of human placenta, in-
fantile hemangioma, and eight normal and diseased
vascularized tissues suggests that high transcriptome simi-
larity is shared between placenta and hemangioma tissues,
more so than any of the other tissues tested [3]. Global
gene expression analysis of infantile hemangioma tumors
has been previously performed by two labs. Ritter et al. [4]
utilized microarray analysis on whole tumors and identi-
fied immune regulators and indoleamine 2,3 dioxygenase
as key regulators of infantile hemangioma involution.
Calicchio et al. [5] utilized laser capture microdissection
and genome-wide transcriptional profiling of vessels from
proliferating and involuting hemangiomas. The authors
strongly associated proliferating hemangioma vessels with
increased expression of genes involved in endothelial-
pericyte interactions and neuronal/vascular patterning,
and involuting hemangiomas with chronic inflammatory
mediators and angiogenic inhibitors. Given the high dens-
ity of tightly associated pericytes in infantile hemangiomas
and the inevitable collateral capture of intraluminal white
cells, fibroblasts, mast cells, and perivascular collagen with
laser microdissection, these data represent changes from
numerous cell types within the infantile hemangioma
tumor, but are not reflective specifically of the aberrant
endothelial cells which contribute to disease. While these
genomics studies have provided great mechanistic insight
into the etiology and progression of the disease, they have
not addressed the unique differences between abnormal
infantile hemangioma endothelial cells and the normal
dermal endothelial cells that are resident in the surroun-
ding skin area of the patient. Understanding these differ-
ences could identify targetable pathways that could be
exploited to preferentially block hemangioma growth and
spread, but spare normal endothelial cells.To date, no direct whole genome comparison of pure
cultures of human dermal microvascular endothelial cells
(HDMVECs) and infantile hemangioma endothelial cells
(HEMECs) has been reported. To address this, we per-
formed whole genome microarray profiling of the gene
expression alterations between low passage pure cultures
of HEMECs and HDMVECs. We identified a number of
transcriptional alterations that are likely to contribute to
the aggressive phenotype of infantile hemangiomas and
that could potentially be utilized in immunotherapy
against particularly aggressive hemangiomas tumors.
Materials and methods
Cell culture and chemicals
The HEMEC cell line was previously isolated from a
proliferating-phase infantile hemangioma specimen col-
lected from a female infant and generously donated to us
by Joyce Bischoff (Harvard Medical School) [6]. The pri-
mary culture of neonatal HDMVECs was purchased from
ATCC. Both cell lines were cultured as previously reported
[7]. For all experiments, cell lines were used at <5 passages.
Proliferation assay
Cells were plated at equivalent sub-confluent densities
and maintained in a Nikon Biostation CT time lapse
imaging station. Cell proliferation was measured by coun-
ting cells per vision field from 5 independent areas over a
96 hour time course. Data presented is the average of the
counts plus or minus the standard deviation. Student’s
t-test was used to evaluate statistical significance. Data
with p<0.05 was considered significant.
Migration assay
Confluent cultures were scratch wounded and the pro-
gress of “wound healing” was monitored using a Nikon
Biostation CT time lapse imaging station over a 9 hour
period. Data presented is the average migration speed
plus or minus the standard deviation. Student’s t-test
was used to evaluate statistical significance (p<0.05).
Data with p<0.05 was considered significant.
Immunofluorescence
Cells were plated onto collagen type I coated glass
coverslips, fixed in 4% paraformaldehyde, and incubated
with antibodies against phospho-focal adhesion kinase
(p-FAK; 1:1000; Cell Signaling #3283), rhodamine conju-
gated phalloidin (1:350; Cytoskeleton Inc.), or DAPI and
imaged via a Nikon Eclipse Ti laser scanning confocal
microscope.
Microarray analysis
Total RNA was amplified and biotin-labeled using
Illumina TotalPrep RNA Amplification Kit (Ambion).
750 ng of biotinylated aRNA was then briefly heat-
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overnight. Following hybridization, arrays were labeled
with Cy3-streptavidin and imaged on the Illumina ISCAN.
Intensity values were transferred to Agilent GeneSpring
GX microarray analysis software and data was filtered
based on quality of each call. Statistical relevance was
determined using ANOVA with a Benjamini Hochberg
FDR multiple testing correction (p-value < 0.05). Data







































Figure 1 Analysis of HDMVEC and HEMEC phenotypes. (A) Analysis of
course. (B) Analysis of the migration rates of HDMVECs and HEMECs nine h
imaging of actin (red), p-FAK (green), and nucleus (blue). (red asterisks for p
determined by Student’s t-test).relevant data points demonstrating a 2-fold or more
change in expression. Pathway analysis was performed
using Metacore software. The microarray data from this
experiment is publically available on the Gene Expression
Omnibus (GEO Accession #GSE43742).
Quantitative real time PCR analysis
RNA was isolated from cells using the Ambion Purelink
Minikit according to the manufacturer’s directions. qRT-HEMECs







proliferation rates between HDMVECs and HEMECs over a 48 hr time
ours after initial scratch from a micropipette. (C) Immunofluorescent
anels A & B represent statistically significant values [p<0.05] as
Table 1 Fold changes in mRNA expression levels of genes in HEMECs compared to HDMVECs
Gene symbol Gene name Accession number FC
CTAG2 Cancer/testis antigen 2 NM_020994.3 11.6
IL13RA2 Interleukin 13 Receptor, alpha 2 NM_000640.2 10.7
IFI27 Interferon, alpha-inducible protein 27 NM_005532.3 8.3
TPM2 Tropomyosin 2 (beta) NM_213674.1 7.8
RPL14 Ribosomal protein L14 NM_001034996.1 6.6
CCNA1 Cyclin A1 NM_003914.3 6.6
RGS5 G-protein signaling 5 regulator NM_003617.3 6.0
FBN2 Fibrillin 2 NM_001999.3 5.9
D4S234E DNA segment on chromosome 4 (unique) NM_001040101.1 5.5
BST2 Bone marrow stromal cell antigen 2 NM_004335.2 5.1
QPCT Glutaminyl-peptide cyclotransferase NM_012413.3 4.8
TNFSF4 Tumor necrosis factor (ligand) superfamily, member 4 NM_003326.3 4.6
RGS5 Regulator of G-protein signaling 5 NM_003617.3 4.6
SPOCK1 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1 NM_004598.3 4.6
SNHG8 Small nucleolar RNA host gene 8 (non-protein coding) NR_003584.3 4.6
ANTXR1 Anthrax toxin receptor 1 NM_032208.2 4.5
CHST1 Carbohydrate sulfotransferase 1 NM_003654.5 4.5
MPZL2 Myelin protein zero-like 2 NM_005797.3 4.4
HEY2 Hairy/enhancer-of-spilt related with YRPW motif 2 NM_012259.2 4.3
SLITRK4 SLIT and NTRK-like family, member 4 NM_173078.3 4.2
SHISA2 Shisa homolog 2 NM_001007538.1 4.0
LRRC17 Leucine rich repeat containing 17, TV2 NM_005824.2 3.9
NUDT11 Nudix-type motif 11 NM_018159.3 3.8
RNASE1 Ribonuclease, Rnase A family, 1, TV1 NM_198235.2 3.7
SERPINE2 Serpin peptidase inhibitor, clade E, member 2 NM_006216.3 3.6
LIPG Lipase, endothelial NM_006033.2 3.4
PCSK5 Proprotein convertase subtilisin/kexin type 5 NM_006200.3 3.4
LPXN Leupaxin NM_004811.2 3.3
CXCR4 Chmeokine (C-X-C motif) receptor 4, TV2 NM_003467.2 3.2
TMEM200A Transmembrane protein 200A NM_052913.2 3.1
CXCR4 Chemokine (C-X-C motif) receptor 4, TV1 NM_001008540.1 3.1
RAB34 RAB34, member RAS onogene family NM_031934.5 3.0
DPYSL3 Dihydropyrimidinase-like 3 NM_001387.2 2.9
FBXL13 F-box and leucine-rich repeat protein 13 NM_145032.3 2.9
PNMA2 Paraneoplastic Ma antigen 2 NM_007257.5 2.9
LOC440354 LOC440354 NR_002473.2 2.9
NLGN1 Neuroligin 1 NM_014932.2 2.8
DDIT4 DNA-damage-inducible transcript 4 NM_019058.2 2.8
PFN2 Profilin 2 NM_053024.3 2.8
GABBR2 Gamma-aminobutyric acid B receptor, 2 NM_005458.7 2.8
MEIS2 Meis homeobox 2 NM_172315.2 2.7
PMEPA1 Prostate transmembrane protein, androgen induced 1 NM_199169.2 2.7
LOC647307 LOC647308 XR_039752.1 2.7
PLEK2 Pleckstrin 2 NM_016445.1 2.7
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Table 1 Fold changes in mRNA expression levels of genes in HEMECs compared to HDMVECs (Continued)
CARD11 Caspase recruitment domain family, member 11 NM_032415.4 2.6
SNORD13 Small nucleolar RNA, C/D box 13, small nucleolar RNA NR_003041.1 2.6
GFPT2 Glutamine-fructoce-6-phosphate transaminase 2 NM_005110.2 2.6
FAP Fibroblast activation protein, alpha NM_004460.2 2.6
OCIAD2 OCIA domain containing 2, TV2 NM_152398.2 2.5
F2RL1 Coagulation factor II receptor-like 1 NM_005242.4 2.5
DSTYK Dual serine/threonine and tyrosine protein kinase NM_199462.2 2.5
LOC649497 LOC649498 XM_938576.1 2.5
LOC654194 LOC654195 XM_942669.1 2.5
NYNRIN NYN domain and retroviral integrase containing NM_025081.2 2.5
LOC387763 LOC387764 XM_941665.2 2.5
COL8A1 Collagen, type VIII, alpha 1 NM_020351.3 2.5
MGC39900 MGC39901 XM_936687.1 2.4
LTBP2 Latent transforming growth factor beta binding protein 2 NM_000428.2 2.4
RNASE1 Ribonuclease, Rnase A family, 1, TV3 NM_198232.2 2.4
IFI27L2 Interferon, alpha-inducible protein 27-like 2 NM_032036.2 2.4
SOX4 SRY (sex determining region Y)-box4 NM_003107.2 2.4
LRRC17 Leucine rich repeat containing 17, TV1 NM_001031692.2 2.3
DSE Dermatan sulfate epimerase NM_013352.2 2.3
CD44 CD44 molecule (Indian blood group), TV5 NM_001001392.1 2.3
LOC100131139 LOC100131140 XR_037336.1 2.3
CBS Systathionine-beta-synthase NM_000071.2 2.3
NT5DC2 5'-nucleotidase domain containing 2 NM_022908.2 2.3
NPFFR2 Neuropeptide FF receptor 2 NM_004885.2 2.3
LOC100129685 LOC100129686 XM_001723814.1 2.3
LXN Latexin NM_020169.3 2.3
MEX3B Mex-3 homolog B NM_032246.3 2.3
C1orf54 Chromosome 1 open reading frame 54 NM_024579.3 2.3
HDDC2 HD domain containing 2 NM_016063.2 2.3
LOC648823 LOC648824 XM_943477.1 2.3
CYB5A Cytochrome b5 type A NM_001914.3 2.3
PIR Pirin (iron binding nuclear protein) NM_001018109.2 2.3
GPR37 G protein-coupled receptor 37 NM_005302.2 2.3
PPAPDC1A Phosphatidic acid phosphatase type 2 domain containing 1A NM_001030059.1 2.3
CD44 CD44 molecule (Indian blood group), TV4 NM_001001391.1 2.2
LOC100131905 LOC100131906 XR_039334.1 2.2
CTAG1A Cancer/testis antigen 1A NM_139250.1 2.2
C4orf18 Chromosome 4 open reading frame 18 NM_016613.6 2.2
LDOC1 Leucine zipper, down-regulated in cancer 1 NM_012317.2 2.2
TGFBI Transforming growth factor, beta-induced NM_000358.2 2.2
COL5A2 Collagen, type V, alpha 2 NM_000393.3 2.2
NOX4 NADPH oxidase 4 NM_016931.3 2.2
TSHZ3 Teashirt zinc finger homeobox 3 NM_020856.2 2.2
FNDC3B Fibronectin type III domain containing 3B, TV2 NM_001135095.1 2.2
KIT V-kit NM_001093772.1 2.2
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Table 1 Fold changes in mRNA expression levels of genes in HEMECs compared to HDMVECs (Continued)
ADAM19 ADAM metallopeptidase domain 19 NM_033274.3 2.2
JAM3 Junctional adhesion molecule 3 NM_032801.4 2.1
CGNL1 Cingulin-like 1 NM_032866.4 2.1
COL4A6 Collagen, type IV, alpha 6 NM_001847.2 2.1
BMX BMX non-receptor tyrosine kinase NM_001721.6 2.1
DUSP23 Dual specificity phosphatase 23 NM_017823.3 2.1
MMP2 Matrix metallopeptidase 2 NM_004530.4 2.1
NCAPD2 Non-SMC condensin I complex, subunit D2 NM_014865.3 2.1
CYBRD1 Cytochrome b reductase 1, TV1 NM_024843.2 2.1
FAM89A Family with sequence similarity 89, member A NM_198552.2 2.1
GAS6 Growth arrest-specific 6 NM_000820.2 2.1
S100A13 S100 calcium binding protein A13 NM_001024211.1 2.1
SMARCE1 SWI/SNF related, subfamily e, member 1 NM_003079.4 2.1
LOC643977 LOC643978 XM_932991.1 2.1
LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase NM_001040167.1 2.1
MTMR11 Myotubularin related protein 11 NM_181873.3 2.1
ITGA10 Integrin, alpha 10 NM_003637.3 2.1
PTGFRN Prostaglandin F2 receptor negative regulator NM_020440.2 2.0
LOC644936 Actin, beta pseudogene NR_004845.1 2.0
CPS1 Carbamoyl-phosphate synthase 1, mitochonfrial NM_001875.4 2.0
C18orf56 Chromosome 18 open reading frame 56 NM_001012716.2 2.0
ADA Adenosine deaminase NM_000022.2 2.0
NETO2 Neuropilin and tolliod-like2 NM_018092.4 2.0
DKFZp761P0423 DKFZp761P0424 XM_291277.4 2.0
STC2 Stanniocalcin 2 NM_003714.2 2.0
PRKAR1A Protein kinase, cAMP-dependent, regulatory, type I, alpha NM_002734.3 2.0
EGFLAM EGF-like, fibronectin type III and laminin G domains NM_182801.2 2.0
SPECC1 Sperm antigen with calponin homology, coiled-coil domains 1 NM_001033555.2 2.0
FNDC3B Fibronectin type III domain containing 3B, TV1 NM_022763.3 2.0
THOC3 THO complex 3 NM_032361.2 2.0
COL5A1 Collagen, type V, alpha 1 NM_000093.3 2.0
LANCL1 LanC lantibiotic synthetase component C-like 1 NM_006055.2 2.0
OCIAD2 OCIA domain containing 2, TV1 NM_001014446.1 2.0
LRIG1 Leucine-rich repeats and immunoglobulin-like domains 1 NM_015541.2 2.0
HOXB2 Homeobox B2 NM_002145.3 2.0
TIMP1 TIMP metallopeptidase inhibitor 1 NM_003254.2 −2.0
NAAA N-acylethanolamine acid amidase NM_014435.3 −2.0
MAOA Monoamine oxidase A NM_000240.2 −2.0
MYOF Myoferlin NM_013451.3 −2.0
KISS1 KiSS metastasis-suppressor NM_002256.3 −2.0
SLC25A22 Solute carrier family 25, member 22 NM_024698.5 −2.0
NOSIP Nitric oxide synthase interacting protein NM_015953.3 −2.0
COL1A2 Collagen, type I, alpha 2 NM_000089.3 −2.0
ZDHHC14 Zinc finger, DHHC-type containing 14 NM_024630.2 −2.0
HPCAL1 Hippocalcin-like 1 NM_134421.1 −2.0
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Table 1 Fold changes in mRNA expression levels of genes in HEMECs compared to HDMVECs (Continued)
VLDLR Very low density lipoprotein receptor NM_001018056.1 −2.0
LOC730525 LOC730525 XM_001126202.1 −2.0
BMP2 Bone morphogenetic protein 2 NM_001200.2 −2.0
ABLIM1 Actin binding LIM protein 1 NM_006720.3 −2.0
PIK3C2A Phosphoinositide-3-kinase, class 2, alpha polypeptide NM_002645.2 −2.0
IRF1 Interferon regulatory factor 1 NM_002198.2 −2.0
MBP Myelin basic protein NM_001025100.1 −2.0
PRKAR1B Protein kinase, cAMP-dependent, regulatory type I, beta NM_002735.2 −2.1
FAM101B Family with sequence similarity 101, member B NM_182705.2 −2.1
ERCC2 DNA excision repair protein 2 NM_000400.3 −2.1
CCND2 Cyclin D2 NM_001759.3 −2.1
HLA-B Major histocompatibility complex, class I, B NM_005514.6 −2.1
SYBU Syntabulin NM_001099743.1 −2.1
PDE2A Phosphodiesterase 2A, cGMP-stimulated NM_002599.4 −2.1
AKAP12 A kinase anchor protein 12 NM_005100.3 −2.1
CLEC2B C-type lectin domain family 2, member B NM_005127.2 −2.1
S100A4 S100 calcuim binding protein A4 NM_019554.2 −2.1
FST Follistain NM_013409.2 −2.2
SLC30A3 Solute carrier family 30, member 3 NM_003459.4 −2.2
PLIN2 Perilipin 2 NM_001122.3 −2.2
IL32 Interleukin 32 NM_001012633.1 −2.2
LOC100128252 LOC100128253 XM_001725603.1 −2.2
TIMM22 Translocase of inner mitochondrial membrane 22 homolog NM_013337.2 −2.2
SYNM Synemin, intermediate filament protein NM_015286.5 −2.2
LOC729985 LOC729986 XM_001131964.1 −2.2
ADRB2 Adrenergic, beta-2-, receptor surface NM_000024.5 −2.2
KIAA1274 KIAA1274 NM_014431.2 −2.2
PRR5 Proline rich 5 NM_001017529.2 −2.2
LOC387841 LOC387842 XM_932678.1 −2.3
CFI Complement factor I NM_000204.3 −2.3
LOC646836 LOC646837 XM_001718162.1 −2.3
COL1A1 Collagen, type I, alpha 1 NM_000088.3 −2.3
CCL2 Chemokine (C-C motif) ligand 2 NM_002982.3 −2.3
COL6A1 Collagen, type VI, alpha 1 NM_001848.2 −2.3
LOC201651 LOC201652 XR_017321.2 −2.3
GALNTL4 GalNAc-T-like protein 4 NM_198516.2 −2.3
S100A3 S100 calcuim binding protein A3 NM_002960.1 −2.4
ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 NM_000689.4 −2.4
TNFRSF14 Tumor necosis factor receptor superfamily, member 14 NM_003820.2 −2.4
CAV1 Caveolin 1 NM_001753.4 −2.4
LAMC2 Laminin, gamma 2 NM_005562.2 −2.4
NOSTRIN Nitric oxide synthase trafficker NM_052946.3 −2.4
CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1 NM_001024912.2 −2.4
CYYR1 Cysteine/tyrosine-rich 1 NM_052954.2 −2.5
SLC22A23 Solute carrier family 22, member 23 NM_021945.5 −2.5
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Table 1 Fold changes in mRNA expression levels of genes in HEMECs compared to HDMVECs (Continued)
ACSL5 Acyl-CoA synthetase long-chain family member 5 NM_016234.3 −2.5
AADAC Arylacetamide deacetylase NM_001086.2 −2.6
COLEC12 Collectin sub-family member 12 NM_130386.2 −2.6
KIAA1324L KIAA1324-like NM_152748.3 −2.6
RNASET2 Ribonuclease T2 NM_003730.4 −2.6
NXN Nucleoredoxin NM_022463.4 −2.6
PLA2G4C Phospholipase A2, group IVC NM_003706.2 −2.6
SERPINB2 Serpin peptidase inhibitor, clade B, member 2 NM_002575.2 −2.6
CETP Cholesteryl ester transfer protein, plasma NM_000078.2 −2.7
PLA2G16 Phospholipase A2, group XVI NM_007069.3 −2.7
TNFSF18 Tumor necrosis factor superfamily, member 18 NM_005092.3 −2.8
CITED2 Cbp/p300-interacting transactivator 2 NM_006079.3 −2.8
C10orf116 Chromosome 10 open reading fame 116 NM_006829.2 −2.8
PROX1 Prospero homeobox 1 NM_002763.3 −2.9
PALM Paralemmin NM_002579.2 −2.9
ZSCAN18 Zinc finger and SCAN domain containing 18 NM_023926.4 −2.9
LEPREL1 Leprecan-like 1 NM_018192.3 −2.9
CTSH Cathepsin H NM_004390.3 −2.9
KHDRBS3 RNA-binding protein T-Star NM_006558.1 −3.0
CDH11 Cadherin 11, type 2, OB-cadherin NM_001797.2 −3.1
DDIT4L DNA-damage-inducible transcript 4-like NM_145244.3 −3.2
GAPDHL6 GAPDHL7 XM_001726954.1 −3.2
NR5A2 Nuclear receptor subfamily 5, group A, member 2 NM_003822.3 −3.3
ABCA3 ATP-binding cassette, sub-family A, member 3 NM_001089.2 −3.3
MARCH2 Membrane-associated ring finger 2 NM_001005416.1 −3.3
CDKN2A Cyclin-dependent kinase inhibitor 2A NM_000077.4 −3.3
MGP Matrix Gla protein NM_000900.3 −3.3
ALDH1A2 Aldehyde dehydrogenase 1 family, member A2 NM_170697.2 −3.5
HOXB7 Homeobox B7 NM_004502.3 −3.5
EMCN Endomucin NM_016242.3 −3.5
ANGPT2 Angiopoietin 2 NM_001147.2 −3.5
GIMAP5 GTPase, IMAP family member 5 NM_018384.4 −3.6
NDN Necdin homolog NM_002487.2 −3.8
TACSTD2 Tumor associate calcuim signal transducer 2 NM_002353.2 −3.8
KRT19 Keratin 19 NM_002276.4 −3.8
FAM174B Family with sequence similarity 174, member B NM_207446.2 −3.9
CECR1 Cat eye syndrome chromosome region, candidate 1 NM_177405.1 −4.2
GPR116 G protein-coupled receptor 116 NM_015234.4 −4.3
TNFRSF6B Tumor necrosis factor superfamily, member 6b, decoy NM_032945.2 −4.3
PIEZO2 Piezo-type mechanosensitive ion channel component 2 NM_022068.2 −4.4
UCHL1 Ubiquitin carboxyl-terminal esterase L1 NM_004181.4 −4.9
KBTBD11 Kelch repeat and BTB domain containing 11 NM_014867.2 −5.3
LOC375295 LOC375296 XM_374020.4 −5.5
HSD17B2 Hydroxysteroid dehydrogenase 2 NM_002153.2 −8.4
LYVE1 Lymphatic vessel endothelial hyaluronan receptor 1 NM_006691.3 −8.8
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Table 1 Fold changes in mRNA expression levels of genes in HEMECs compared to HDMVECs (Continued)
PDPN Podoplanin NM_001006625.1 −15.8
GYPC Glycophorin C NM_016815.3 −22.6
MMP1 Matrix metallopeptidase 1 NM_002421.3 −25.8
FABP4 Fatty acid binding protein 4, adipocyte NM_001442.2 −28.1
CLDN11 Claudin 11 NM_005602.5 −36.9
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using TaqMan Assays with predesigned primer sets for
the genes of interest (Invitrogen). All RT-PCR experi-
ments were performed in triplicate.Immunohistochemistry
Paraffinized infantile hemangioma tissues were labeled
with CTAG2 antibody (1:200, Santa Cruz Biotechnology
#sc99243) and quantified using Alkaline Phosphatase de-
tection (CellMarque). Positive and negative controls
from breast carcinoma tissues were stained with CTAG2
antibody or sham, respectively. Use of de-identified hu-
man tissues was approved by the Texas Tech University
Health Sciences Center Institutional Review Board for
the Protection of Human Subjects (IRB E13029). Waiver
of informed consent was approved by IRB.Table 2 qPCR confirmation of a subset of gene
expression changes in HEMECs compared to HDMVECs
Gene Expression Δ
RGS5 92.4 ± 11.2
CTAG2 39.9 ± 4.8
SMARCE1 4.4 ± 1.4
LTBP2 3.3 ± 0.5
ANGPT2 −2.1 ± 0.3
KISS1 −2.5 ± 0.4
ANTXR1 −2.8 ± 0.4
CLDN11 −10.0 ± 0.9
p≤0.05 for all values.Results and discussion
A comparison of the proliferation and migration rates of
HEMECs and HDMVECs under standard growth condi-
tions revealed no significant difference between normal
and hemangioma endothelial cell types, however HEMECs
grown under reduced serum conditions (0.5% fetal bovine
serum) exhibited an approximately 30% increase in pro-
liferation and an approximately 18% increase in migration
relative to HDMVECs grown under the same conditions
(Figure 1A & B). This suggests the higher serum con-
centrations were likely masking any phenotypic advantage
attributed to the HEMECs. Moreover, it indicates the
proliferative and migratory capacity of HEMECs are
unique from that observed in HDMVECs and agrees with
earlier reports suggesting advantages in these areas for
HEMECs [6]. Comparisons of fluorescent images of the
actin cytoskeleton and active focal adhesion comple-
xes obtained with confocal microscopy revealed that
HDMVECs display primarily peripheral membrane loca-
lized p-FAK, indicating sites of cellular attachment to the
extracellular matrix (ECM) (Figure 1C). In contrast,
p-FAK localization in HEMECs was observed along the
entirety of the actin stress fibers, suggesting cellular
adhesion to its substrate is markedly altered in HEMECs.
Indeed, it has previously been reported that HEMECs
display unique expression of genes involved in cellular
adhesion [8].Whole genome microarray analysis reveals large scale
alterations in gene expression between HEMECs and
HDMVECs
Given the phenotypic differences observed between
HEMECs and HDMVECs, we compared the global gene
expression patterns between pure cultures of these cells
using Illumina high density BeadArrays to elucidate
which molecular factors are deregulated in HEMECs.
Our array analysis identified 125 genes whose expression
was upregulated and 104 genes whose expression was
downregulated (2 fold or greater, p<0.05) in HEMECs
compared to HDMVECs (Table 1). Metacore analysis of
the 2 fold or greater gene expression changes revealed
three major classifications of gene functions that are
altered in HEMECs including cell adhesion (TIMP1,
COL1A1, COL1A2, MMP1, MMP13, SERPINE2, COL4A6,
LAMC2, MMP2, CD44, CAV1, CCL2, JAM3, CLDN11,
LYVE1), cell cycle (CCND2, CDKN2A, CCNA1, NCAPD2),
and arachidonic acid production (ACSL5, FAP, LIPG,
PLA2G4C). Given the number of adhesion genes whose
expression is altered in HEMECs compared to HDMVECs,
it is no surprise that we observed altered subcellular
localization of p-FAK in HEMECs (Figure 1C), reflecting a
unique adhesive phenotype in these cells. Our data re-
flect altered cell cycle regulation in HEMECs, with a
downregulation of CCND2 (cyclin D2) and CDKN2A
(p16Ink4A) and a potent 6.6 fold increase in CCNA1
(cyclin A1), and these changes may contribute to the
enhanced proliferation rates in HEMECs and the uncon-
trolled cell growth observed in infantile hemangiomas
tumors. Alterations in the expression of genes involved in
Neonatal Foreskin
























Figure 2 Detection of CTAG2 protein levels in infantile hemangioma tissues. Proliferating and involuting infantile hemangioma tissues as
well as normal neonatal foreskin tissues were cut from paraffin blocks, incubated with antibodies against CTAG2, and detected using alkaline
phosphatase staining (red). Immunohistochemistry (IHC) controls included incubations without CTAG2 antibody (negative control) and with CTAG2
antibody (positive control) in thin sections from metastatic breast cancer. All images were obtained at 100X total magnification.
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unsaturated fatty acid can serve as a lipid second messen-
ger in the regulation of phospholipase-C and protein
kinase-C signaling, is a key inflammatory intermediate,
and can act as a vasodilator [9].
We confirmed a small subset of these gene expression
changes utilizing qPCR, revealing equivocal trends in gene
expression between the microarray and qPCR data for
ANGPT2, ANTXR1, SMARCE1, RGS5, CTAG2, LTBP2,
CLDN11, and KISS1 (Table 2). Each of these genes has
been firmly established to play critical roles in regulatingangiogenesis and/or tumor progression [10-17]. Missense
mutations in ANTXR1 have been reported in several
infantile hemangiomas and contribute to the constitutive
VEGFR2 signaling associated with these tumors [18].
Mutations and signaling aberrations in Tie2, the cognate
receptor for ANGPT2, play central roles in the develop-
ment of various vascular disorders [19,20]. ANGPT2 has
previously been shown to be down-regulated in response
to serum in HEMECs [19]. Interestingly, ANGPT2 expres-
sion is higher in HEMECs compared to normal placental
endothelial cells and is increased in proliferative infantile
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ally undetectable in normal vasculature, RGS5 is greatly
upregulated in the vasculature of solid tumors and may
have the potential to serve as a tumor biomarker [12]. The
downregulation of the metastasis suppressor KISS1 that
we observed in HEMECs may partially explain the locally
aggressive properties of infantile hemangiomas, as this
gene encodes an angiogenic suppressor [16,21]. Moreover,
the expression of KISS1 is markedly reduced in aggressive
metastatic melanomas and breast cancers, and this loss of
expression contributes to the metastatic phenotype of
these cells [17,22]. It is intriguing that such genes (particu-
larly the cancer-specific genes) are aberrantly expressed in
HEMECs, and undoubtedly their deregulation could
potentiate aberrant vascular tumor states. As it has been
proposed that infantile hemangiomas may be derived from
motile placental-derived chorangioma cells [2], future
genomics analysis should compare the transcriptomes of
each tumor type to identify if aberrant expression of
tumor-related genes is shared between the tissues.
Overexpression of the CTAG2 cancer/testis antigen in a
panel of infantile hemangioma tumors
In our microarray analysis, the cancer/testis antigen
CTAG2 displayed the highest upregulation of mRNA
expression in HEMECs compared to the HDMECs. This
gene, whose function is completely unknown, has been
shown to be significantly increased in several metastatic
cancers, and is actively being researched as a target of
immune therapy for aggressive cancers [23-29]. If CTAG2
is preferentially upregulated in infantile hemangiomas, it
is possible that treatment of disfiguring or life threatening
infantile hemangioma tumors could employ immune the-
rapy against this antigen. Furthermore, CTAG2 is reported
to be a target for antigen-specific T-cells in patients with
various metastatic tumors [29,30]. A recent study has
shown that nearly half of the patients with spontaneous
CTAG2-specific CD4(+) T cell responses had circulating
CTAG2-specific antibodies that recognized epitopes lo-
cated in the C-terminal portion of CTAG2 [30]. As
involution of infantile hemangiomas is believed to be due
in part to an immune mediated attack on the tumor itself
[4], it is possible that T-cell targeting of the overexpressed
CTAG2 protein could contribute to this process. We
confirmed our microarray data at the protein level by
performing immunohistochemistry on a panel of 16 para-
ffin embedded infantile hemangioma tumors representing
both the proliferating and involuting stages of the disease
and 4 normal neonatal dermal tissues. A limited amount
of CTAG2 expression was observed in the normal dermal
tissues (a few nerve cells and bundles present staining,
whereas the fibroblasts and collagen fibers are negative),
and despite this gene being coined a “cancer/testis specific
antigen”, analysis of publically available microarraydatasets suggests this gene is expressed at a low level
across a large number of tissues (www.biogps.org) and it
has been reported in the literature to be expressed in the
placenta and ovary [31]. In proliferating tumors (composed
of densely proliferating endothelial cells), we observed
intense CTAG2 staining in the endothelial cells for all
sections analyzed (Figure 2). In contrast, involuting tumors
(marked by substantial adipocyte deposits—a characteristic
of the later stages in the development of this tumor [32])
exhibited significantly reduced levels of CTAG2 staining.
As Calicchio et al. did not detect significant differences in
CTAG2 expression between microdissected endothelial
cells from proliferating and involuting infantile hema-
ngiomas and the staining intensity of individual blood
vessels appears relatively constant between proliferating
and involuting hemangiomas, we suspect that the reduced
CTAG2 staining in involuting tumors is most likely due to
reductions in tumor vascular density but not changes in
gene transcription.
Conclusion
Our data indicate that global transcriptional expression
patterns are markedly unique between pure cultures of
HDMVECs and HEMECs with major alterations in cell
cycle, adhesion, and arachidonic acid metabolism genes.
Though considered benign, HEMECs showed surprising
aberrant regulation in the expression of several genes
involved in tumor progression. Our finding that CTAG2
is highly expressed in infantile hemangiomas may lead to
the development of immune-mediated therapies against
infantile hemangiomas.
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